Eli Lilly's experimental GLP-1 medication retatrutide produced average weight loss of 49.6 pounds in people with Type 2 diabetes at the highest dose over 80 weeks, with those having higher BMI losing even more. The company plans to seek FDA approval as a biologic drug before March 2027, a classification that would provide longer market exclusivity than alternative categories.